HK1204261A1 - Immunogenic wt-1 peptides and methods of use thereof wt-1 - Google Patents

Immunogenic wt-1 peptides and methods of use thereof wt-1

Info

Publication number
HK1204261A1
HK1204261A1 HK15104710.4A HK15104710A HK1204261A1 HK 1204261 A1 HK1204261 A1 HK 1204261A1 HK 15104710 A HK15104710 A HK 15104710A HK 1204261 A1 HK1204261 A1 HK 1204261A1
Authority
HK
Hong Kong
Prior art keywords
immunogenic
peptides
methods
Prior art date
Application number
HK15104710.4A
Other languages
English (en)
Chinese (zh)
Inventor
Richard J Oreilly
Ekaterina Doubrovina
Annamalai Selvakumar
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of HK1204261A1 publication Critical patent/HK1204261A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK15104710.4A 2012-01-13 2015-05-18 Immunogenic wt-1 peptides and methods of use thereof wt-1 HK1204261A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261586177P 2012-01-13 2012-01-13
US201261647207P 2012-05-15 2012-05-15
PCT/US2013/021448 WO2013106834A2 (en) 2012-01-13 2013-01-14 Immunogenic wt-1 peptides and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1204261A1 true HK1204261A1 (en) 2015-11-13

Family

ID=48782099

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104710.4A HK1204261A1 (en) 2012-01-13 2015-05-18 Immunogenic wt-1 peptides and methods of use thereof wt-1

Country Status (8)

Country Link
US (3) US20150104413A1 (xx)
EP (2) EP2802347B1 (xx)
JP (2) JP6282598B2 (xx)
CN (2) CN104684577B (xx)
AU (2) AU2013207669C1 (xx)
CA (1) CA2861206C (xx)
HK (1) HK1204261A1 (xx)
WO (1) WO2013106834A2 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6282598B2 (ja) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ１ペプチド及びその使用方法
EP3640375A3 (en) 2012-12-11 2020-07-29 Albert Einstein College of Medicine Methods for high throughput receptor/ligand identification
WO2015164826A2 (en) * 2014-04-24 2015-10-29 Rhode Island Hospital ASPARTATE-β-HYDROXYLASE INDUCES EPITOPE-SPECIFIC T CELL RESPONSES IN TUMORS
CN108350411B (zh) * 2015-06-25 2021-06-22 白川利朗 口服肿瘤疫苗
MX2018002816A (es) * 2015-09-10 2018-06-08 Memorial Sloan Kettering Cancer Center Metodos de tratamiento de mieloma multiple y leucemia de celulas plasmaticas mediante terapia de celulas t.
EP3362929B1 (en) * 2015-10-12 2020-08-12 Nantomics, LLC Viral neoepitopes and uses thereof
AU2016356708B2 (en) 2015-11-20 2022-02-03 Memorial Sloan Kettering Cancer Center Methods and compositions for treating cancer
IL262606B2 (en) 2016-05-18 2023-04-01 Albert Einstein College Medicine Inc pd-l1 variant polypeptides, T-cell modulatory multimeric polypeptides, and methods of using them
JP7071288B2 (ja) 2016-05-18 2022-05-18 キュー バイオファーマ， インコーポレイテッド Ｔ細胞調節多量体ポリペプチド及びその使用方法
CN110506107A (zh) 2016-11-30 2019-11-26 阿德瓦希斯公司 靶向复发性癌症突变的免疫原性组合物及其使用方法
SI3558339T1 (sl) 2016-12-22 2024-05-31 Cue Biopharma, Inc. Celico T modulirajoči multimerni polipeptidi in postopki njihove uporabe
EP4032911A1 (en) 2017-01-06 2022-07-27 Eutilex Co., Ltd. Anti-human 4-1bb antibodies and use thereof
WO2018129474A1 (en) 2017-01-09 2018-07-12 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
IL309479A (en) 2017-03-15 2024-02-01 Cue Biopharma Inc Methods for modulating an immune response
CN111315768A (zh) 2017-09-07 2020-06-19 库尔生物制药有限公司 具有缀合位点的t细胞调节性多聚体多肽及其使用方法
SG11202004107YA (en) * 2017-11-08 2020-06-29 Advaxis Inc Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
EP3737689A4 (en) 2018-01-09 2021-12-01 Cue Biopharma, Inc. MULTIMERIC T CELL-MODULATING POLYPEPTIDES AND METHOD OF USING THEREOF
EP3801597A4 (en) * 2018-05-25 2022-05-04 The Wistar Institute TUMOR-SPECIFIC NEOANTIGENS AND METHODS OF USE
WO2020132366A2 (en) * 2018-12-19 2020-06-25 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
CN110423723A (zh) * 2019-07-18 2019-11-08 南方医科大学南方医院 一种外周血b细胞系的构建方法及其应用
KR20220129567A (ko) 2019-12-31 2022-09-23 엘릭서젠 쎄라퓨틱스, 인크. 핵산 및 단백질의 세포 및 조직으로의 온도-기반 일시적 전달
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
EP4211149A1 (en) 2020-09-09 2023-07-19 Cue Biopharma, Inc. Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA8748A (en) 1878-05-04 George W. Ainsworth Improvements on clothes dryers
CA23766A (en) 1886-04-06 Albert M. Todd Process of, and appartus for treating essential oils to obtain the concrete or crystalline part thereof separate and apart from the liquid portion
CA59350A (en) 1898-02-26 1898-03-19 Thomas Henry Simmonds Brake for velocipede, tricycle, etc.
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5837249A (en) 1985-04-19 1998-11-17 The Wistar Institute Method for generating an immunogenic T cell response protective against a virus
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
US5229115A (en) 1990-07-26 1993-07-20 Immunex Corporation Adoptive immunotherapy with interleukin-7
CA2103577A1 (en) 1991-02-07 1992-08-08 Michael Kahn Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
EP0692973A1 (en) 1993-03-15 1996-01-24 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Peptide coated dendritic cells as immunogens
WO1995029240A1 (en) 1994-04-22 1995-11-02 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Isolation and characterization of a novel primate t-cell lymphotropic virus and the use of this virus or components thereof in diagnostics assays and vaccines
US5622835A (en) 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US5643786A (en) 1995-01-27 1997-07-01 The United States Of America As Represented By The Department Of Health And Human Services Method for isolating dendritic cells
US6156316A (en) 1995-05-08 2000-12-05 Sloan-Kettering Institute For Cancer Research Oncogene fusion protein peptide vaccines
JPH11171896A (ja) 1995-09-19 1999-06-29 Kirin Brewery Co Ltd 新規ペプチド化合物およびその医薬組成物
US5981217A (en) 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
AU1394497A (en) 1996-01-17 1997-08-11 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6207375B1 (en) 1996-12-11 2001-03-27 Mayo Foundation For Medical Educational & Research TGF-β inducible early factor-1 (TIEF-1) and a method to detect breast cancer
ID27813A (id) 1998-01-28 2001-04-26 Corixa Corp Senyawa-senyawa untuk terapi dan diagnosa kanker paru-paru dan metoda untuk penggunaannya
CN1560078B (zh) 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
US7115272B1 (en) 1998-09-30 2006-10-03 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7063854B1 (en) * 1998-09-30 2006-06-20 Corixa Corporation Composition and methods for WTI specific immunotherapy
US20120301492A1 (en) 1998-09-30 2012-11-29 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
US7655249B2 (en) 1998-09-30 2010-02-02 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7901693B2 (en) 1998-09-30 2011-03-08 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US7329410B1 (en) 1998-09-30 2008-02-12 Corixa Corporation Compositions and method for WT1 specific immunotherapy
US7144581B2 (en) 2000-10-09 2006-12-05 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
US20030072767A1 (en) 1998-09-30 2003-04-17 Alexander Gaiger Compositions and methods for WT1 specific immunotherapy
GB9823897D0 (en) 1998-11-02 1998-12-30 Imp College Innovations Ltd Immunotherapeutic methods and molecules
WO2000037491A2 (en) 1998-12-22 2000-06-29 Genset Dnas encoding proteins with signal sequences
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
CA2367692A1 (en) 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
US6593299B1 (en) * 1999-04-21 2003-07-15 University Of Florida Research Foundation, Inc. Compositions and methods for controlling pests
WO2001025273A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for wt1 specific immunotherapy
CA2401070A1 (en) * 2000-02-22 2001-08-30 Corixa Corporation Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20030082194A1 (en) 2000-02-22 2003-05-01 Alexander Gaiger Compositions and methods for diagnosis and therapy of malignant mesothelioma
US20040002068A1 (en) 2000-03-01 2004-01-01 Corixa Corporation Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US6861234B1 (en) 2000-04-28 2005-03-01 Mannkind Corporation Method of epitope discovery
EP1209226A3 (en) 2000-11-07 2002-06-05 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Maturation of dendritic cells by recombinant heat shock protein 70 (hsp70)
CA2440303C (en) 2001-03-22 2013-03-19 Haruo Sugiyama Wt1 modified peptide
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
WO2003002142A1 (en) 2001-06-29 2003-01-09 Chugai Seiyaku Kabushiki Kaisha Cancer vaccine containing cancer antigen based on tumor suppressor gene wt1 product and cationic liposomes
US7553494B2 (en) 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
JPWO2003028758A1 (ja) 2001-09-28 2005-01-13 治夫 杉山 抗原特異的ｔ細胞の誘導方法
US8735357B2 (en) 2001-09-28 2014-05-27 International Institute Of Cancer Immunology, Inc. Method of inducing antigen-specific T cells
US20030072761A1 (en) 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030175272A1 (en) 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
ATE466084T1 (de) 2002-06-12 2010-05-15 Int Inst Cancer Immunology Inc Hla-a24-restringiertes krebsantigenpeptid
MXPA05008340A (es) 2003-02-06 2006-03-13 Cerus Corp Microbios de vida libre modificados, composiciones de vacuna y metodos de uso de los mismos.
US20050008618A1 (en) 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
ES2527946T3 (es) * 2003-03-05 2015-02-02 Dendreon Corporation Composiciones y métodos que emplean polipéptidos de marco de lectura alternativa para el tratamiento de cáncer y enfermedades infecciosas
ES2478446T3 (es) 2003-06-27 2014-07-22 International Institute Of Cancer Immunology, Inc. Método de selección de pacientes candidatos para la vacuna contra WT1
US20050147621A1 (en) 2003-10-10 2005-07-07 Higgins Darren E. Use of bacterial 5' untranslated regions for nucleic acid expression
KR101213015B1 (ko) 2003-11-05 2012-12-26 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ１ 로부터 유도된 ｈｌａ-ｄｒ 결합성 항원 펩티드
US7488718B2 (en) * 2003-12-01 2009-02-10 Sloan Kettering Institue For Cancer Research Synthetic HLA binding peptide analogues and uses thereof
ES2484340T3 (es) 2003-12-05 2014-08-11 Multimmune Gmbh Anticuerpos anti hsp70 terapéuticos y diagnósticos
EP1550458A1 (en) 2003-12-23 2005-07-06 Vectron Therapeutics AG Synergistic liposomal adjuvants
EP1720565A1 (en) 2004-03-04 2006-11-15 Corixa Corporation Co-encapsulated wt1 polypeptide and immunostimulant microsphere formulations and methods thereof
US20050214268A1 (en) 2004-03-25 2005-09-29 Cavanagh William A Iii Methods for treating tumors and cancerous tissues
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
SI1731605T1 (sl) 2004-03-31 2010-07-30 Internat Inst Of Cancer Immunolog Inc Peptidi antigena karcinoma izvedeni iz WT1
US9629927B2 (en) 2005-07-29 2017-04-25 Sloan-Kettering Institute For Cancer Research Single wall nanotube constructs and uses thereof
AU2006304573B2 (en) 2005-10-17 2012-05-24 Sloan Kettering Institute For Cancer Research WT1 HLA class II-binding peptides and compositions and methods comprising same
CN101336249A (zh) * 2005-11-30 2008-12-31 株式会社癌免疫研究所 新型肽化合物
PL1988163T3 (pl) 2006-02-22 2012-11-30 Int Inst Cancer Immunology Inc Ograniczony do hla-a*3303 peptyd wt1 i zawierająca go kompozycja farmaceutyczna
JP5231997B2 (ja) 2006-03-29 2013-07-10 株式会社癌免疫研究所 ＷＴ１１７ＡＡ（−）アイソフォーム特異的ｓｉＲＮＡおよびその利用
WO2007120603A2 (en) 2006-04-10 2007-10-25 Sloan Kettering Institute For Cancer Research Immunogenic bcr-abl peptides and methods of use thereof
EP3117836A1 (en) 2006-04-10 2017-01-18 Sloan Kettering Institute For Cancer Research Immunogenic wt-1 peptides and uses thereof
NZ619576A (en) 2006-12-27 2014-07-25 Harvard College Compositions and methods for the treatment of infections and tumors
CA2886619A1 (en) 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same
KR101323540B1 (ko) 2007-02-07 2013-10-29 사이단호진한다이비세이부쯔뵤우겐큐우카이 암의 치료제
CN104774910B (zh) 2007-02-27 2018-04-10 株式会社癌免疫研究所 活化辅助t细胞的方法以及用于该方法的组合物
AR066676A1 (es) 2007-05-24 2009-09-02 Glaxosmithkline Biolog Sa Composicion antigenica liofilizada que contiene un agonista del receptor tipo toll
KR100995340B1 (ko) 2007-11-19 2010-11-19 재단법인서울대학교산학협력재단 자연 살해 ｔ 세포의 리간드와 항원을 적재한 단핵구 또는미분화 골수성 세포를 포함하는 백신
TWI455721B (zh) 2007-12-05 2014-10-11 Int Inst Cancer Immunology Inc 癌疫苗組合物
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
WO2009143085A1 (en) 2008-05-19 2009-11-26 Anza Therapeutics, Inc. Compositions comprising prfa*mutant listeria and methods of use thereof
EP2337795A2 (en) * 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
AR076349A1 (es) 2009-04-23 2011-06-01 Int Inst Cancer Immunology Inc Peptido auxiliar del antigeno del cancer
WO2011059835A2 (en) 2009-11-11 2011-05-19 Quest Diagnostics Investments Incorporated Wt1 mutations for prognosis of myeloproliferative disorders
US20110136141A1 (en) 2009-12-03 2011-06-09 Abbott Laboratories Peptide reagents and method for inhibiting autoantibody antigen binding
WO2011100754A1 (en) 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
JP2013536240A (ja) 2010-08-24 2013-09-19 ユニヴァーシティ オヴ ピッツバーグ オヴ ザ コモンウェルス システム オヴ ハイアー エデュケーション インターロイキン−１３受容体α２ペプチド脳がんワクチン
ES2849187T3 (es) 2010-10-05 2021-08-16 Int Inst Cancer Immunology Inc Método para activar células T auxiliares
PE20140405A1 (es) 2011-03-11 2014-03-22 Gilead Calistoga Llc Terapias combinadas para malignidades hematologicas
US9803246B2 (en) 2011-06-28 2017-10-31 International Institute Of Cancer Immunology, Inc. Receptor gene for peptide cancer antigen-specific T cell
US9783821B2 (en) 2011-07-29 2017-10-10 Riken Cell for use in immunotherapy which contains modified nucleic acid construct encoding wilms tumor gene product or fragment thereof, method for producing said cell, and said nucleic acid construct
US9539299B2 (en) 2011-10-27 2017-01-10 International Institute Of Cancer Immunology, Inc. Combination therapy with WT1 peptide vaccine and temozolomide
CN104136609B (zh) 2011-12-14 2016-12-07 国立大学法人高知大学 辅助性t细胞诱导多肽的修饰
JP6282598B2 (ja) 2012-01-13 2018-02-21 メモリアル スローン ケタリング キャンサー センター 免疫原性ｗｔ１ペプチド及びその使用方法
US9303079B2 (en) 2012-04-02 2016-04-05 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
JP6251734B2 (ja) 2012-05-03 2017-12-27 フレッド ハッチンソン キャンサー リサーチ センター 親和性増強型ｔ細胞受容体およびその作製方法
ES2655031T3 (es) 2012-07-02 2018-02-16 Sumitomo Dainippon Pharma Co., Ltd. Preparación transdérmica de péptido antigénico del cáncer
CN109106945B (zh) 2012-10-23 2023-04-18 优比维克有限责任公司 用于治疗疾病的同种异体自噬体富集组合物
JP6530192B2 (ja) 2012-12-17 2019-06-12 大塚製薬株式会社 ヘルパーｔ細胞の活性化方法
CN104968782B (zh) 2012-12-26 2019-09-06 生物科莫公司 利用人副流感2型病毒载体的疫苗
CN116789792A (zh) 2013-01-15 2023-09-22 纪念斯隆凯特林癌症中心 免疫原性wt-1肽和其使用方法
EP2762160A1 (en) 2013-02-05 2014-08-06 Nitto Denko Corporation Wt1 peptide cancer vaccine composition for mucosal administration
RU2697443C2 (ru) 2013-02-05 2019-08-14 Нитто Денко Корпорейшн Препарат противораковой вакцины, содержащий пептид wt1, в форме ленты трансдермального введения
RU2687144C2 (ru) 2013-02-05 2019-05-07 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащей пептид wt1, для трансдермального введения
US10071051B2 (en) 2013-02-05 2018-09-11 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
CA2898474A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Cancer vaccines and vaccination methods
JP6294868B2 (ja) 2013-03-12 2018-03-14 大日本住友製薬株式会社 液体水性組成物
CN114225019A (zh) 2013-03-15 2022-03-25 宾夕法尼亚大学理事会 癌疫苗及使用其的治疗方法
DK2982681T3 (en) 2013-03-29 2018-12-10 Sumitomo Dainippon Pharma Co Ltd WT1 ANTIGENPEPTIDKONJUGATVACCINE
EP2988762B1 (en) 2013-04-25 2018-06-06 Vaximm AG Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1
ES2954899T3 (es) 2013-05-13 2023-11-27 Int Inst Cancer Immunology Inc Procedimiento para predecir el efecto clínico de una inmunoterapia
WO2015002134A1 (ja) 2013-07-02 2015-01-08 公益財団法人がん研究会 細胞性免疫誘導ワクチン
MX2016006625A (es) 2013-11-22 2016-12-02 Univ Illinois Receptores de células t humanas con alta afinidad modificados por medio de manipulación genética.
LT3082850T (lt) 2013-12-18 2019-11-11 Vaximm Gmbh Į msln nukreipta dnr vakcina vėžio imunoterapijai
KR20220062143A (ko) 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
EP3112378B1 (en) 2014-02-26 2020-06-24 Tella, Inc. Wt1 antigenic polypeptide, and anti-tumor agent containing said polypeptide
US10023841B2 (en) 2014-05-23 2018-07-17 Baylor Research Institute Methods and compositions for treating breast cancer with dendritic cell vaccines
CA2970236A1 (en) 2014-12-11 2016-06-16 International Institute Of Cancer Immunology, Inc. Compositions comprising wt1 peptide for immunotherapy of angiogenic disease
CN108350411B (zh) 2015-06-25 2021-06-22 白川利朗 口服肿瘤疫苗
US20190054112A1 (en) 2015-09-18 2019-02-21 Moderna Therapeutics, Inc. Polynucleotide formulations for use in the treatment of renal diseases

Also Published As

Publication number Publication date
JP6282598B2 (ja) 2018-02-21
AU2018201210A1 (en) 2018-03-08
JP2018104438A (ja) 2018-07-05
US10815274B2 (en) 2020-10-27
EP3520810A3 (en) 2019-11-06
JP2015512866A (ja) 2015-04-30
JP6995645B2 (ja) 2022-01-14
US20170334951A1 (en) 2017-11-23
EP2802347A4 (en) 2016-06-01
CN108676069A (zh) 2018-10-19
AU2013207669A1 (en) 2014-08-07
AU2018201210B2 (en) 2020-04-09
EP3520810A2 (en) 2019-08-07
CA2861206A1 (en) 2013-07-18
EP2802347B1 (en) 2019-01-09
CN104684577B (zh) 2018-05-08
AU2013207669B9 (en) 2017-12-14
EP2802347A2 (en) 2014-11-19
US20150104413A1 (en) 2015-04-16
AU2013207669C1 (en) 2018-05-31
WO2013106834A3 (en) 2015-01-22
US20190092813A1 (en) 2019-03-28
CA2861206C (en) 2021-07-06
AU2013207669B2 (en) 2017-11-23
CN104684577A (zh) 2015-06-03
US10100087B2 (en) 2018-10-16
WO2013106834A2 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
HK1204261A1 (en) Immunogenic wt-1 peptides and methods of use thereof wt-1
SI2945647T1 (sl) Imunogeni peptidi WT-1 in postopki za uporabo le-teh
EP2912178A4 (en) SUPER AMPLIFIER AND METHOD FOR USE THEREOF
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
HK1199892A1 (en) Modified mini-hepcidin peptides and methods of using thereof
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
PT2925782T (pt) Anticorpos anti-cd47 e métodos de utilização destes
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
EP2895083A4 (en) LIGATOR AND METHOD FOR ITS USE
EP2870170A4 (en) NOVEL PEPTIDES AND THEIR USE
IL238227A0 (en) Antibodies against c16orf54 and uses thereof
HK1206037A1 (en) Human antibodies to gfr3 and methods of use thereof gfr3
HK1197187A1 (en) Anti-lrp5 antibodies and methods of use lrp5
EP2782589A4 (en) ANTIMICROBIAL PEPTIDES AND METHOD FOR THEIR USE
HK1225645A1 (zh) Pcv2b趨異株疫苗組合物以及使用方法
EP2863858A4 (en) PATIENT DISPOSAL SYSTEMS AND METHOD OF USE
EP2806811A4 (en) VERTEBRAL CONSTRUCTION
HK1203161A1 (en) Peptides and methods of using same
EP2897639A4 (en) IMPROVED VACCINE COMPOSITIONS AND METHODS OF USE
EP2938632A4 (en) ANTI-GRANULYSIN ANTIBODIES AND METHODS OF USE
EP2852397A4 (en) HUWENTOXIN IV VARIANTS AND METHODS OF USE
HK1209432A1 (en) Anti-jagged antibodies and methods of use
SG11201504805PA (en) Porcine parvovirus 5a, methods of use and vaccine
EP2897680A4 (en) INFLATION DEVICES AND APPLICATION METHOD
EP2925341A4 (en) PEPTIDE COMPOUNDS AND METHODS OF MAKING AND USING THEM